Analgesic Efficacy of Smoked Cannabis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00241579|
Recruitment Status : Completed
First Posted : October 19, 2005
Last Update Posted : June 23, 2006
|Condition or disease||Intervention/treatment||Phase|
|Pain Hyperalgesia||Drug: Smoked Cannabis||Phase 1 Phase 2|
It is important to evaluate the effects of the cannabinoids on facilitated pain as conditions of hyperalgesia more closely approximates the clinical situation. There are limited clinical studies on the effect of the cannabinoids on facilitated pain states. Noyes et al evaluated the analgesic effects of Delta-9-THC in 34 cancer patients with pain. They concluded that 20mg of oral Delta-9-THC was similar to 120mg of codeine (Noyes et al, 1975). Jain et al concluded that 1.5-3mg of intramuscular Levonantradol resulted in significant pain relief as compared to placebo in 56 patients with acute postoperative pain (Jain et al, 1981).
Comparison(s): Three different doses of smoked cannabis will be compared to placebo for the reduction of experimentally induced pain.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||15 participants|
|Intervention Model:||Crossover Assignment|
|Official Title:||Analgesic Efficacy of Smoked Cannabis|
|Study Start Date :||February 2002|
|Estimated Study Completion Date :||January 2004|
- Score on a Visual Analog Scale (VAS) of pain severity
- McGill Pain Questionnaire (MPQ) Short Form
- Neurosensory testing of: 1) warm and cold sensation, 2) warm and cold pain, 3) touch, and 4) mechanical pain. Testing administered using a Thermal Sensory Analyzer, von Frey hair filaments, and a pinch algometer, respectively.
- Trail Making Test (TMT) as a measure of psychomotor speed.
- Paced Auditory Serial Attention Test (PASAT) as a measure of speed of information processing.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00241579
|United States, California|
|UC San Diego Medical Center|
|San Diego, California, United States, 92093|
|Principal Investigator:||Mark Wallace, M.D.||University of California, San Diego|